GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operatio...(y data for the full dose of the GeoVax A...)

This trial will serve as a major milestone, as the Phase 2a trial is

the most advanced trial to-date for GeoVax. HVTN and the clinical

trial sites are moving forward with the administrative steps

necessary to prepare for commencement of the Phase 2a trial, which

GeoVax expects to begin before the end of the year.

* In October 2008, GeoVax announced that its company information is

now available via Standard and Poor's Market Access Program, an

information distribution service that enables subscribing

publicly-traded companies to have their company information

disseminated to users of Standard and Poor's Advisor Insight.

GeoVax's company information is also available via Standard & Poor's

Stock Guide database, which is distributed electronically to

virtually all major quote vendors. These services will help GeoVax

comply with numerous state "Blue Sky" laws to ensure that its stock

is made available to the broadest possible investor base.

* On October 15, 2008, GeoVax presented data on its Phase 1 AIDS

vaccine trial (HVTN 065) at the AIDS Vaccine 2008 conference, in

Cape Town, South Africa. The presentation, entitled "Two HIV DNA

Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA

Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN

065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor,

Division of Infectious Diseases, Department of Medicine, University

of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The

trial results reveal the GeoVax DNA and MVA vaccines are safe and

immunogenic (stimulate anti-HIV/AIDS immune responses) at both low

(1/10th) dose and full dose
'/>"/>